AMRI sees Q1 drops, but maintains positive financial outlook for 2012

As Albany Molecular Research ($AMRI) progresses into 2012, it is driven to recoup revenue it lost out on in the first quarter.

In its first-quarter financial report, AMRI earned $53.7 million, a 6% decrease compared with $56.9 million earned by the CMO in the first quarter of 2011. Contract revenue for discovery services and small scale manufacturing also took hits, suffering 8% and 7% decreases respectively compared with a year earlier. Large scale manufacturing, however, enjoyed a 6% increase, earning $23.2 million, as opposed to $21.8 million a year earlier.

In an effort to up revenue, AMRI made a notable sacrifice to close its facility in Budapest, Hungary, laying off 100 employees and saving what should amount to an estimated $14 million, as the Albany Business Review reports. Services typically performed in Hungary will be transferred to Asia, which AMRI states will enhance customer service, something it wants to repair, coming off a harsh FDA review that found violations at AMRI's facility in Massachusetts last year.

Still, AMRI has lot to fall back on. It also secured a $20 million credit line with Wells Fargo and improved its net income by $6.5 million, according to its financial report. AMRI flourished last month, winning a research and development deal with Biota to work on a flu antiviral and an option with Bessor Pharma to license AMRI's tubulin inhibitor program.

As CFO Mark Frost describes, AMRI has a positive financial forecast for the rest of this year. "For the full year 2012, we continue to expect contract revenue to range from $176 million to $186 million, an increase of up to 10% versus 2011," he said.

- read the financial report
- more from Albany Business Review

Related Stories:
AMRI gets research and manufacturing deal for Biota's flu antiviral
Albany Molecular shutters facility in Hungary, axing 100
AMRI out to win customers back

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.